Information  X 
Enter a valid email address

Ergomed plc (ERGO)

  Print   

Thursday 29 April, 2021

Ergomed plc

Board Changes

RNS Number : 9928W
Ergomed plc
29 April 2021
 

 PRESS RELEASE

 

Board Changes

 

Dr. Llew Keltner appointed as Non-Executive Director

 

Guildford, UK - 29 April 2021: Ergomed plc (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, today announces that Dr. Llew Keltner, M.D., Ph.D., will join the Board as a Non-Executive Director with immediate effect. The Company also announces that Non-Executive Director, Ian Johnson, is stepping down from the Ergomed Board to focus on his other Board roles.

 

Dr. Keltner brings over 30 years of experience across the life sciences sector, holding various senior positions with a particular focus on oncology and rare diseases. He has extensive experience of public and private financings, M&A, the formation of strategic partnerships and numerous transactions in the CRO, biotech and pharma sectors. While Chairman of Raptor Pharmaceuticals Inc., a US rare disease company, he led multiple financing rounds, product launches and the eventual sale of the Company to Horizon Pharmaceuticals in 2016. He was also a member of the Board of Mannkind Corporation through its successful Nasdaq listing, and Immunovaccine Inc. through several successful fundraises.

 

Dr. Keltner holds the positions of Associate Professor at Case Western Reserve School of Medicine, and Director and Lecturer in Bioethics at Columbia School of Medicine, as well as authoring numerous research papers. He is currently on the Scientific Advisory Boards of several life sciences companies across the United States. He holds an MD and a PhD in Biomedical Informatics, both from Case Western Reserve University in Cleveland.

 

Dr Miroslav Reljanović, Executive Chairman of Ergomed, commented: "Llew's outstanding track record in the life sciences industry, with particular focus in oncology and rare disease in the US and globally, will be an invaluable asset for Ergomed. This experience, together with his strong links to the US pharmaceutical and investment communities, are fully aligned with the Company's strategy to continue our expansion in the US and build our global specialist leadership position. Llew will be a great addition to Ergomed's Board and on behalf of the Board, I warmly welcome him to his new role.

 

"I would also like to thank Ian for his contribution and support of Ergomed throughout his time on the Board. We wish him all the best for the future."  

 

Dr Llew Keltner said: "Having seen the success and rapid rate of growth at Ergomed, it is hugely exciting to be joining the team. The growth in both the CRO business and PrimeVigilance has been impressive to watch from outside and the addition of two US acquisitions has transformed the company's presence and capabilities in the US market. I am looking forward to working with the Board and contributing my expertise in life sciences and US investor relations as the Company continues on its high growth trajectory and becomes a global leader in its chosen markets."

 

 

Dr Llew Keltner, aged 71, holds or has held directorships in the five years preceding his appointment at Ergomed as follows:

 

Current Directorships

Previous Directorships

YK Bio LLC

Raptor Pharmaceuticals Inc

Infostat Systems Inc


BioQ Pharma


Light Sciences Oncology


EPISTAT


Surgeon Training International, LLC


Vesselon Inc


OncoSCAR


 

Save as disclosed above there are no additional disclosures to be made in accordance with Schedule Two paragraph (g) of the AIM Rules.

 

ENDS

 

Enquiries:

Ergomed plc

 Tel: +44 (0) 1483 402 975

Miroslav Reljanović (Executive Chairman)


Richard Barfield (Chief Financial Officer)




Numis Securities Limited

Tel: +44 (0) 20 7260 1000

Freddie Barnfield / Matthew O'Dowd (Nominated Adviser)


James Black (Broker)




Consilium Strategic Communications - for UK enquiries

Tel: +44 (0) 20 3709 5700

Chris Gardner / Matthew Neal

[email protected]

Angela Gray / Olivia Manser




 

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO), and an internationally recognised specialist expertise in orphan drug development, under PSR. For further information, visit: http://ergomedplc.com .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAFFFIFSRITFIL

a d v e r t i s e m e n t